HC Wainwright maintains Alnylam price target at $455
HC Wainwright & Co. maintained its Alnylam Pharmaceuticals price target of $455.00 per share, according to Benzinga/TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.